Digene/Cytyc to commence joint marketing of Hybrid Capture HPV test, ThinPrep Pap test in 1997.
DIAGENE/CYTYC JOINT MARKETING OF HYBRID CAPTURE HPV, THINPREP PAP TESTS will begin in early 1997 under an Oct. 8 strategic alliance between the two firms. Speaking at a same day session of the UBS Securities Life Sciences Conference in New York City, Evan Jones, Digene president and CEO, said joint marketing of Digene's Hybrid Capture human papilloma virus (HPV) DNA test and Cytyc's ThinPrep 2000 automated cervical sample preparation system is anticipated to commence "in the first quarter of 1997."
More from Archive
More from Medtech Insight
Increased support for NHS services and delivery infrastructure announced in the 11 June government spending review by chancellor of the exchequer Rachel Reeves could boost inward investment and offer new market opportunities for medtechs.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Ahead of the 11 June UK spending review and its anticipated funding uplift for healthcare and life sciences, the MHRA announced an expansion of its digital expertise by creating a dedicated hub in Leeds, a renowned center of medtech excellence.